Metabolism of Glycogen 18

Total Page:16

File Type:pdf, Size:1020Kb

Metabolism of Glycogen 18 ch18.qxd 2/13/2003 3:05 PM Page 145 Metabolism of Glycogen 18 Peter A. Mayes, PhD, DSc, & David A. Bender, PhD BIOMEDICAL IMPORTANCE phatase catalyzes hydrolysis of pyrophosphate to 2 mol of inorganic phosphate, shifting the equilibrium of the Glycogen is the major storage carbohydrate in animals, main reaction by removing one of its products. corresponding to starch in plants; it is a branched poly- α Glycogen synthase catalyzes the formation of a gly- mer of -D-glucose. It occurs mainly in liver (up to 6%) coside bond between C of the activated glucose of and muscle, where it rarely exceeds 1%. However, be- 1 UDPGlc and C4 of a terminal glucose residue of glyco- cause of its greater mass, muscle contains about three to gen, liberating uridine diphosphate (UDP). A preexist- four times as much glycogen as does liver (Table 18–1). ing glycogen molecule, or “glycogen primer,” must be Muscle glycogen is a readily available source of glu- present to initiate this reaction. The glycogen primer cose for glycolysis within the muscle itself. Liver glyco- may in turn be formed on a primer known as glyco- gen functions to store and export glucose to maintain genin, which is a 37-kDa protein that is glycosylated blood glucose between meals. After 12–18 hours of on a specific tyrosine residue by UDPGlc. Further glu- fasting, the liver glycogen is almost totally depleted. cose residues are attached in the 1→4 position to make Glycogen storage diseases are a group of inherited dis- a short chain that is a substrate for glycogen synthase. orders characterized by deficient mobilization of glyco- In skeletal muscle, glycogenin remains attached in the gen or deposition of abnormal forms of glycogen, lead- center of the glycogen molecule (Figure 13–15), ing to muscular weakness or even death. whereas in liver the number of glycogen molecules is greater than the number of glycogenin molecules. GLYCOGENESIS OCCURS MAINLY IN MUSCLE & LIVER Branching Involves Detachment The Pathway of Glycogen Biosynthesis of Existing Glycogen Chains Involves a Special Nucleotide of Glucose The addition of a glucose residue to a preexisting glyco- (Figure 18–1) gen chain, or “primer,” occurs at the nonreducing, outer end of the molecule so that the “branches” of the As in glycolysis, glucose is phosphorylated to glucose glycogen “tree” become elongated as successive 1→4 6-phosphate, catalyzed by hexokinase in muscle and linkages are formed (Figure 18–3). When the chain has glucokinase in liver. Glucose 6-phosphate is isomer- been lengthened to at least 11 glucose residues, branch- ized to glucose 1-phosphate by phosphoglucomutase. ing enzyme transfers a part of the 1→4 chain (at least The enzyme itself is phosphorylated, and the phospho- six glucose residues) to a neighboring chain to form a group takes part in a reversible reaction in which glu- 1→6 linkage, establishing a branch point. The cose 1,6-bisphosphate is an intermediate. Next, glucose branches grow by further additions of 1→4-glucosyl 1-phosphate reacts with uridine triphosphate (UTP) to units and further branching. form the active nucleotide uridine diphosphate glu- cose (UDPGlc)* and pyrophosphate (Figure 18–2), catalyzed by UDPGlc pyrophosphorylase. Pyrophos- GLYCOGENOLYSIS IS NOT THE REVERSE OF GLYCOGENESIS BUT IS A SEPARATE * Other nucleoside diphosphate sugar compounds are known, eg, PATHWAY (Figure 18–1) UDPGal. In addition, the same sugar may be linked to different nucleotides. For example, glucose may be linked to uridine (as Glycogen phosphorylase catalyzes the rate-limiting shown above) as well as to guanosine, thymidine, adenosine, or cy- step in glycogenolysis by promoting the phosphorylytic tidine nucleotides. cleavage by inorganic phosphate (phosphorylysis; cf hy- 145 ch18.qxd 2/13/2003 3:05 PM Page 146 146 / CHAPTER 18 Glycogen → → (1 4 and 1 6 glucosyl units)x BRANCHING ENZYME Pi (1→4 Glucosyl units) x Insulin UDP GLYCOGEN cAMP GLYCOGEN SYNTHASE PHOSPHORYLASE Glycogen primer Glucagon Epinephrine GLUCAN * TRANSFERASE Glycogenin DEBRANCHING Uridine ENZYME disphosphate glucose (UDPGlc) To uronic acid Free glucose from pathway debranching UDPGlc PYROPHOSPHORYLASE enzyme INORGANIC PYROPHOSPHATASE PPi 2 Pi Uridine UDP triphosphate (UTP) Glucose 1-phosphate 2+ Mg PHOSPHOGLUCOMUTASE Glucose 6-phosphate To glycolysis and pentose phosphate pathway H O ADP NUCLEOSIDE 2 DIPHOSPHO- GLUCOSE-6- + ATP ADP Mg2 GLUCOKINASE KINASE PHOSPHATASE Pi ATP Glucose Figure 18–1. Pathway of glycogenesis and of glycogenolysis in the liver. Two high-energy phosphates are used in the incorporation of 1 mol of glucose into glycogen. ᭺+ , stimulation; ᭺− , inhibition. Insulin decreases the level of cAMP only after it has been raised by glucagon or epinephrine—ie, it antagonizes their action. Glucagon is active in heart muscle but not in skeletal muscle. At asterisk: Glucan transferase and debranching enzyme ap- pear to be two separate activities of the same enzyme. Table 18–1. Storage of carbohydrate in postabsorptive normal adult humans (70 kg). drolysis) of the 1→4 linkages of glycogen to yield glu- cose 1-phosphate. The terminal glucosyl residues from the outermost chains of the glycogen molecule are re- Liver glycogen 4.0% = 72 g1 2 moved sequentially until approximately four glucose Muscle glycogen 0.7% = 245 g → Extracellular glucose 0.1% = 10 g3 residues remain on either side of a 1 6 branch (Figure 18–4). Another enzyme (␣-[1v4]v␣-[1v4] glucan 327 g transferase) transfers a trisaccharide unit from one → 1Liver weight 1800 g. branch to the other, exposing the 1 6 branch point. 2Muscle mass 35 kg. Hydrolysis of the 1→6 linkages requires the de- 3Total volume 10 L. branching enzyme. Further phosphorylase action can ch18.qxd 2/13/2003 3:05 PM Page 147 METABOLISM OF GLYCOGEN / 147 O dephosphorylation of enzyme protein in response to 6CH2OH hormone action (Chapter 9). HN H O Uracil Cyclic AMP (cAMP) (Figure 18–5) is formed from H H 1 O N ATP by adenylyl cyclase at the inner surface of cell OH H O O membranes and acts as an intracellular second messen- HO O P O P O CH2 ger in response to hormones such as epinephrine, nor- H OH O – O – O epinephrine, and glucagon. cAMP is hydrolyzed by phosphodiesterase, so terminating hormone action. In HH Ribose liver, insulin increases the activity of phosphodiesterase. HH HO OH Phosphorylase Differs Between Glucose Diphosphate Uridine Liver & Muscle Figure 18–2. Uridine diphosphate glucose (UDPGlc). In liver, one of the serine hydroxyl groups of active phosphorylase a is phosphorylated. It is inactivated by hydrolytic removal of the phosphate by protein phos- phatase-1 to form phosphorylase b. Reactivation re- then proceed. The combined action of phosphorylase quires rephosphorylation catalyzed by phosphorylase and these other enzymes leads to the complete break- kinase. down of glycogen. The reaction catalyzed by phospho- Muscle phosphorylase is distinct from that of liver. It glucomutase is reversible, so that glucose 6-phosphate is a dimer, each monomer containing 1 mol of pyridoxal can be formed from glucose 1-phosphate. In liver (and phosphate (vitamin B6). It is present in two forms: phos- kidney), but not in muscle, there is a specific enzyme, phorylase a, which is phosphorylated and active in either glucose-6-phosphatase, that hydrolyzes glucose the presence or absence of 5′-AMP (its allosteric modi- 6-phosphate, yielding glucose that is exported, leading fier); and phosphorylase b, which is dephosphorylated to an increase in the blood glucose concentration. and active only in the presence of 5′-AMP. This occurs during exercise when the level of 5′-AMP rises, providing, CYCLIC AMP INTEGRATES THE by this mechanism, fuel for the muscle. Phosphorylase a is REGULATION OF GLYCOGENOLYSIS the normal physiologically active form of the enzyme. & GLYCOGENESIS cAMP Activates Muscle Phosphorylase The principal enzymes controlling glycogen metabo- lism—glycogen phosphorylase and glycogen synthase— Phosphorylase in muscle is activated in response to epi- are regulated by allosteric mechanisms and covalent nephrine (Figure 18–6) acting via cAMP. Increasing modifications due to reversible phosphorylation and the concentration of cAMP activates cAMP-dependent 1→4- Glucosidic bond Unlabeled glucose residue 1→6- Glucosidic bond 14C-labeled glucose residue 14C-Glucose → added New 1 6- bond GLYCOGEN BRANCHING SYNTHASE ENZYME Figure 18–3. The biosynthesis of glycogen. The mechanism of branching as revealed by adding 14C-labeled glucose to the diet in the living animal and examining the liver glycogen at further intervals. ch18.qxd 2/13/2003 3:05 PM Page 148 148 / CHAPTER 18 types of subunits—α, β, γ, and δ—in a structure repre- αβγδ α β sented as ( )4. The and subunits contain serine residues that are phosphorylated by cAMP-dependent protein kinase. The δ subunit binds four Ca2+ and is identical to the Ca2+-binding protein calmodulin (Chapter 43). The binding of Ca2+ activates the cat- alytic site of the γ subunit while the molecule remains in the dephosphorylated b configuration. However, the phosphorylated a form is only fully activated in the presence of Ca2+. A second molecule of calmodulin, or TpC (the structurally similar Ca2+-binding protein in muscle), can interact with phosphorylase kinase, caus- ing further activation. Thus, activation of muscle con- PHOSPHORYLASE GLUCAN DEBRANCHING traction and glycogenolysis are carried out by the same TRANSFERASE ENZYME Ca2+-binding protein, ensuring their synchronization. Glucose residues joined by 1 → 4- glucosidic bonds Glycogenolysis in Liver Can Glucose residues joined by Be cAMP-Independent → 1 6- glucosidic bonds In addition to the action of glucagon in causing forma- tion of cAMP and activation of phosphorylase in liver, Figure 18–4. Steps in glycogenolysis. ␣ 1-adrenergic receptors mediate stimulation of glyco- genolysis by epinephrine and norepinephrine. This in- volves a cAMP-independent mobilization of Ca2+ protein kinase, which catalyzes the phosphorylation by from mitochondria into the cytosol, followed by the ATP of inactive phosphorylase kinase b to active stimulation of a Ca2+/calmodulin-sensitive phosphory- phosphorylase kinase a, which in turn, by means of a lase kinase.
Recommended publications
  • Phosphorylation of Mcardle Phosphorylase Induces Activity (Human Skeletal Muscle/Protein Kinase) CESARE G
    Proc. Nati. Acad. Sci. USA Vol. 78, No. 5, pp. 2688-2692, May 1981 Biochemistry Phosphorylation of McArdle phosphorylase induces activity (human skeletal muscle/protein kinase) CESARE G. CERRI AND JOSEPH H. WILLNER Department of Neurology and H. Houston Merritt Clinical Research Center for Muscular Dystrophy and Related Diseases, Columbia University College of Physicians and Surgeons, New York, New York 10032 Communicated by Harry Grundfest, January 7, 1981 ABSTRACT In McArdle disease, myophosphorylase defi- mediate between those of phosphorylases b and a. Karpatkin ciency, enzyme activity is absent but the presence of an altered et al. (19, 20) found that incubation of human platelets with enzyme protein can frequently be demonstrated. We have found MgATP+ resulted in an increase in total phosphorylase activity that phosphorylation of this protein in vitro can result in catalytic and concluded that the data were "consistent with the presence activity. We studied muscle of four patients; all lacked myophos- in human platelets of inactive dimer and monomer species of phorylase activity, but myophosphorylase protein was demon- phosphorylase, which require MgATP for activation." Because strated by immunodiffusion or gel electrophoresis. Incubation of activation of these isozymes was probably due to protein phos- muscle homogenate supernatants with cyclic AMP-dependent pro- phorylation and also because incomplete phosphorylation could tein kinase and ATP resulted in phosphorylase activity. The ac- tivated enzyme comigrated with normal human myophosphory- result in reduced activity, we evaluated the possibility that the lase in gel electrophoresis. Incubation with [y-32P]ATP resulted activity ofphosphorylase in McArdle muscle could be restored in incorporation of 32P into the band possessing phosphorylase by phosphorylation of the inactive phosphorylase protein pres- activity.
    [Show full text]
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • (Glycogen Storage Disease Type V) and Anesthesia a Case Report And
    Pediatric Anesthesia ISSN 1155-5645 REVIEW ARTICLE McArdle’s disease (glycogen storage disease type V) and anesthesia – a case report and review of the literature Georg Bollig1,2 1 Department of Anesthesiology and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, Schleswig, Germany 2 Department of Surgical Sciences, Haukeland University Hospital, University of Bergen, Bergen, Norway Keywords Summary general anesthesia; glycogen storage disease; glycogen storage disease type V; McArdles disease (glycogen storage disease type v) is a rare condition in malignant hyperthermia; McArdles disease; which energy-metabolism in the muscle is hampered. A case report is pre- perioperative complications sented and the possible risk for perioperative complications including malig- nant hyperthermia is discussed. A checklist for the anesthesiological Correspondence management of patients with McArdles disease is provided. A short overview Georg Bollig, Department of Anesthesiology of anesthesiological challenges and perioperative complications of other gly- and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, cogen storage diseases is given. Schleswig, Germany Email: [email protected] Section Editor: Barbara Brandom Accepted 3 March 2013 doi:10.1111/pan.12164 tachycardia and hypotonia occurred. After the opera- Introduction tion, the anesthesiologist informed the patient about the McArdle’s disease is a rare condition in which energy event and the fact that he had elevated liver enzymes metabolism in the muscle is hampered. A case report (aspartate transaminase = AST, alanine transaminase = will be presented, and the possible risk of perioperative ALT, and lactate dehydrogenase = LDH). An overview problems including malignant hyperthermia is dis- of the patient’s anesthesiological history is given in cussed.
    [Show full text]
  • Guaiacol As a Drug Candidate for Treating Adult Polyglucosan Body Disease
    Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon, … , Wyatt W. Yue, H. Orhan Akman JCI Insight. 2018;3(17):e99694. https://doi.org/10.1172/jci.insight.99694. Research Article Metabolism Therapeutics Graphical abstract Find the latest version: https://jci.me/99694/pdf RESEARCH ARTICLE Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon,1 Igor Ferreira,2 Leonardo J. Solmesky,3 Netaly Khazanov,4 Alexander Lossos,1 Rafael Alvarez,5 Deniz Yetil,6 Sergey Pampou,7 Miguel Weil,3,8 Hanoch Senderowitz,4 Pablo Escriba,5 Wyatt W. Yue,2 and H. Orhan Akman9 1Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.3 Cell Screening Facility for Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 4Department of Chemistry, Bar Ilan University, Ramat Gan, Israel. 5Laboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain. 6Connecticut College, Newington, Connecticut USA. 7Columbia University Department of Systems Biology Irving Cancer Research Center, New York, New York, USA. 8Laboratory for Neurodegenerative Diseases and Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty for Life Sciences, Sagol School of Neurosciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. 9Columbia University Medical Center Department of Neurology, Houston Merritt Neuromuscular diseases research center, New York, New York, USA. Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency.
    [Show full text]
  • A Genome Based Discovery of S. Mansoni Secretome to Identify Therapeutic Targets
    ics om & B te i ro o P in f f o o Mandage et al. J Proteomics Bioinform 2011, 4:3 r l m a Journal of a n t r i c u DOI: 10.4172/jpb.1000168 s o J ISSN: 0974-276X Proteomics & Bioinformatics Research Article Article OpenOpen Access Access A Genome Based Discovery of S. mansoni Secretome to Identify Therapeutic Targets Mandage RH1*, Jadhavrao PK2, Wadnerkar AS1, Varsale AR1 and Kurwade KK1 1Dept of Bioinformatics, Centre for Advanced Life Sciences, Deogiri College, Aurangabad 431005, M.S. India 2Dept of Microbiology, Abeda Inamdar College, Pune 411001, M.S. India Abstract The motivation behind the large scale genome analysis of S. mansoni was to explore the possibility of discovering the secretome that is frequently secreted at the interface of parasite and host is supposed to play a crucial role in parasitism by suppressing the immune response, to aid the proliferation of infectivity. Here, we present an efficient pipeline of bioinformatics methodology to identify candidate parasitism proteins within S. mansoni secretome of immune responses in the infected host. The 3,700 proteins deduced from the S. mansoni genome were analysed for the presence or absence of secretory signal peptides. We identified 32 proteins carrying an N-terminal secreted signal peptide but deficient in extra membrane-anchoring moieties. Notably we identified proteins involved in ATP synthesis, redox balance, protein folding, gluconeogenesis, development and signaling, scavenging and nucleotide metabolic pathways, immune response modulation. Most of these proteins define their potential for immunological diagnosis and vaccine design. A systematic attempt has been made here to develop a general method for predicting secretory proteins of a parasite with high efficiency and accuracy.
    [Show full text]
  • An Evolving Hierarchical Family Classification for Glycosyltransferases
    doi:10.1016/S0022-2836(03)00307-3 J. Mol. Biol. (2003) 328, 307–317 COMMUNICATION An Evolving Hierarchical Family Classification for Glycosyltransferases Pedro M. Coutinho1, Emeline Deleury1, Gideon J. Davies2 and Bernard Henrissat1* 1Architecture et Fonction des Glycosyltransferases are a ubiquitous group of enzymes that catalyse the Macromole´cules Biologiques transfer of a sugar moiety from an activated sugar donor onto saccharide UMR6098, CNRS and or non-saccharide acceptors. Although many glycosyltransferases catalyse Universite´s d’Aix-Marseille I chemically similar reactions, presumably through transition states with and II, 31 Chemin Joseph substantial oxocarbenium ion character, they display remarkable diversity Aiguier, 13402 Marseille in their donor, acceptor and product specificity and thereby generate a Cedex 20, France potentially infinite number of glycoconjugates, oligo- and polysacchar- ides. We have performed a comprehensive survey of glycosyltransferase- 2Structural Biology Laboratory related sequences (over 7200 to date) and present here a classification of Department of Chemistry, The these enzymes akin to that proposed previously for glycoside hydrolases, University of York, Heslington into a hierarchical system of families, clans, and folds. This evolving York YO10 5YW, UK classification rationalises structural and mechanistic investigation, harnesses information from a wide variety of related enzymes to inform cell biology and overcomes recurrent problems in the functional prediction of glycosyltransferase-related open-reading frames. q 2003 Elsevier Science Ltd. All rights reserved Keywords: glycosyltransferases; protein families; classification; modular *Corresponding author structure; genomic annotations The biosynthesis of complex carbohydrates and are involved in glycosyl transfer and thus conquer polysaccharides is of remarkable biological import- what Sharon has provocatively described as “the ance.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Ron Caspi Peter Midford Peter D Karp An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000702945Cyc: Clostridium sp. KNHs205 Cellular Overview Connections between pathways are omitted for legibility.
    [Show full text]
  • Chem331 Glycogen Metabolism
    Glycogen metabolism Glycogen review - 1,4 and 1,6 α-glycosidic links ~ every 10 sugars are branched - open helix with many non-reducing ends. Effective storage of glucose Glucose storage Liver glycogen 4.0% 72 g Muscle glycogen 0.7% 245 g Blood Glucose 0.1% 10 g Large amount of water associated with glycogen - 0.5% of total weight Glycogen stored in granules in cytosol w/proteins for synthesis, degradation and control There are very different means of control of glycogen metabolism between liver and muscle Glycogen biosynthetic and degradative cycle Two different pathways - which do not share enzymes like glycolysis and gluconeogenesis glucose -> glycogen glycogenesis - biosynthetic glycogen -> glucose 1-P glycogenolysis - breakdown Evidence for two paths - Patients lacking phosphorylase can still synthesize glycogen - hormonal regulation of both directions Glycogenolysis (glycogen breakdown)- Glycogen Phosphorylase glycogen (n) + Pi -> glucose 1-p + glycogen (n-1) • Enzyme binds and cleaves glycogen into monomers at the end of the polymer (reducing ends of glycogen) • Dimmer interacting at the N-terminus. • rate limiting - controlled step in glycogen breakdown • glycogen phosphorylase - cleavage of 1,4 α glycosidic bond by Pi NOT H2O • Energy of phosphorolysis vs. hydrolysis -low standard state free energy change -transfer potential -driven by Pi concentration -Hydrolysis would require additional step s/ cost of ATP - Think of the difference between adding a phosphate group with hydrolysis • phosphorylation locks glucose in cell (imp. for muscle) • Phosphorylase binds glycogen at storage site and the catalytic site is 4 to 5 glucose residues away from the catalytic site. • Phosphorylase removes 1 residue at a time from glycogen until 4 glucose residues away on either side of 1,6 branch point – stericaly hindered by glycogen storage site • Cleaves without releasing at storage site • general acid/base catalysts • Inorganic phosphate attacks the terminal glucose residue passing through an oxonium ion intermediate.
    [Show full text]
  • Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion
    Molecular Neurobiology https://doi.org/10.1007/s12035-018-0997-9 Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion Rishibha Sachdev1,2 & Karin Kappes-Horn3 & Lydia Paulsen1 & Yvonne Duernberger1 & Catharina Pleschka1 & Philip Denner1 & Bishwajit Kundu2 & Jens Reimann3 & Ina Vorberg1,4 Received: 30 August 2017 /Accepted: 7 March 2018 # The Author(s) 2018 Abstract Sporadic inclusion body myositis (sIBM) is the most prevalent acquired muscle disorder in the elderly with no defined etiology or effective therapy. Endoplasmic reticulum stress and deposition of myostatin, a secreted negative regulator of muscle growth, have been implicated in disease pathology. The myostatin signaling pathway has emerged as a major target for symptomatic treatment of muscle atrophy. Here, we systematically analyzed the maturation and secretion of myostatin precursor MstnPP and its metabolites in a human muscle cell line. We find that increased MsntPP protein levels induce ER stress. MstnPP metabolites were predominantly retained within the endoplasmic reticulum (ER), also evident in sIBM histology. MstnPP cleavage products formed insoluble high molecular weight aggregates, a process that was aggravated by experimental ER stress. Importantly, ER stress also impaired secretion of mature myostatin. Reduced secretion and aggregation of MstnPP metabolites were not simply caused by overexpression, as both events were also observed in wildtype cells under ER stress. It is tempting to speculate that reduced circulating myostatin growth factor could be one explanation for the poor clinical efficacy of drugs targeting the myostatin pathway in sIBM. Keywords Sporadic inclusion body myositis . ER stress . Myostatin . Amyloid precursor protein . Protein misfolding . Atrophy Introduction [5]. Pathological characteristics include vacuolated mus- cle fibers, deposition of proteinaceous material [6, 7], Sporadic inclusion body myositis (sIBM) is the most and T lymphocyte infiltration [8].
    [Show full text]
  • SEARCH Supplementary Appendix for SLCO1B1 Variants and Statin
    Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy — a genomewide study. N Engl J Med 2008;359. DOI: 10.1056/NEJMoa0801936. Supplementary Appendix for: “SLCO1B1 Variants and Statin-Induced Myopathy – A Genomewide Study” CONTENTS SEARCH Collaborative Group Supplementary Tables Supplementary Table 1: Baseline characteristics of 85 myopathy cases and 90 matched controls in SEARCH Supplementary Table 2a: Associations with myopathy for SNPs within SLCO1B1 (+/- 10kb) from the genome-wide association study, candidate genotyping and imputation in SEARCH Supplementary Table 2b: Associations with myopathy for SNPs within CYP3A4 (+/- 10kb) with myopathy in SEARCH Supplementary Table 3: LDL-cholesterol concentrations and reductions with 40mg simvastatin daily in HPS, subdivided by rs4149056 and rs2306283 SLCO1B1 genotypes Supplementary Table 4: Previous candidate gene studies of statin-induced myopathy, myalgia or intolerance (also included in Supplementary Table 5); and findings for associations of these genes with myopathy in SEARCH Supplementary Table 5: Genes previously reported to be associated with statin-induced myopathy, statin intolerance or statin pharmacokinetics; and associations with SNPs in these genes (+/- 10kb) with myopathy in SEARCH Supplementary Table 6: In vivo studies of the association between statin elimination and SLCO1B1 rs4149056 SNP Supplementary Figure Supplementary
    [Show full text]
  • Comparative Transcriptomics Reveals Lineage Specific Evolution of Cold
    bioRxiv preprint doi: https://doi.org/10.1101/151431; this version posted June 19, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Evolution of cold response in Pooideae 1 Comparative transcriptomics reveals lineage specific evolution of 2 cold response in Pooideae 3 Lars Grønvold1*, Marian Schubert2*, Simen R. Sandve3, Siri Fjellheim2 and Torgeir R. 4 Hvidsten1,4 5 *Contributed equally 6 1Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life 7 Sciences, NO-1432, Ås, Norway. 8 2Department of Plant Sciences, Norwegian University of Life Sciences, Ås NO-1432, Norway. 9 3Centre for Integrative Genetics (CIGENE), Department of Animal and Aquacultural Sciences, 10 Norwegian University of Life Sciences, NO-1432, Ås, Norway. 11 4Umeå Plant Science Centre, Department of Plant Physiology, Umeå University, SE-90187, 12 Umeå, Sweden. 13 Author for correspondence: 14 Torgeir R. Hvidsten 15 Tel: +4767232491 16 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/151431; this version posted June 19, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Evolution of cold response in Pooideae 17 Abstract 18 Background: Understanding how complex traits evolve through adaptive changes in gene 19 regulation remains a major challenge in evolutionary biology.
    [Show full text]
  • Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease
    cells Review Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease Marta Migocka-Patrzałek * and Magdalena Elias Department of Animal Developmental Biology, Faculty of Biological Sciences, University of Wroclaw, 50-335 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Glycogen phosphorylase (PG) is a key enzyme taking part in the first step of glycogenolysis. Muscle glycogen phosphorylase (PYGM) differs from other PG isoforms in expression pattern and biochemical properties. The main role of PYGM is providing sufficient energy for muscle contraction. However, it is expressed in tissues other than muscle, such as the brain, lymphoid tissues, and blood. PYGM is important not only in glycogen metabolism, but also in such diverse processes as the insulin and glucagon signaling pathway, insulin resistance, necroptosis, immune response, and phototransduction. PYGM is implicated in several pathological states, such as muscle glycogen phosphorylase deficiency (McArdle disease), schizophrenia, and cancer. Here we attempt to analyze the available data regarding the protein partners of PYGM to shed light on its possible interactions and functions. We also underline the potential for zebrafish to become a convenient and applicable model to study PYGM functions, especially because of its unique features that can complement data obtained from other approaches. Keywords: PYGM; muscle glycogen phosphorylase; functional protein partners; glycogenolysis; McArdle disease; cancer; schizophrenia Citation: Migocka-Patrzałek, M.; Elias, M. Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells 1. Introduction 2021, 10, 883. https://doi.org/ The main energy substrate in animal tissues is glucose, which is stored in the liver and 10.3390/cells10040883 muscles in the form of glycogen, a polymer consisting of glucose molecules.
    [Show full text]